Allogene Therapeutics: Is The Market Looking At CAR-T Persistence The Wrong Way?

Cema-cel achieved MRD clearance in 58.3% of treated patients vs 16.7% under observation, alongside a 97.7% median ctDNA reduction by day 45 indicating substantial early biological activity. FDA RMAT and Fast Track designations bolster the development strategy, though the article notes they don’t confirm durable efficacy. Overall, the read-through is positive but not definitive for long-term outcomes.